Aa
What is latent HBV and HCV
Study: Hepatitis Linked to Fibromyalgia; polyDNA Recommends Gene-Eden-VIR Against Latent HCV and HBV
Published: November 28, 2013 7:49 AM
A study published on September 25 in The International Journal of Clinical and Experimental Medicine found that Fibromyalgia (FM) “prevalence was found to be as high as 25% in a single study of hepatitis B virus (HBV) carriers (1).” polyDNA recommends Gene-Eden-VIR to help the immune system target the latent HCV and HBV.
Rochester, NY (PRWEB) November 28, 2013
Patients with life-long infections of the hepatitis B and hepatitis C viruses tend to develop Fibromyalgia (FM). “(FM) is a syndrome characterized by widespread and chronic musculoskeletal pain, fatigue, morning stiffness, and sleep disturbance. The condition affects middle-aged women, in particular, and FM prevalence in the general population is thought to be as high as 2% (1).” However, “the prevalence of FM is higher in patients with Lyme disease, and those with HIV and hepatitis C virus (HCV) infections (1).” In addition, “FM prevalence was found to be as high as 25% in a single study of hepatitis B virus (HBV) carriers (1).” Compare the numbers, 2% in the general population versus 25% in hepatitis B patients.
Researchers found that Fibromyalgia was more prevalent in those with a latent HBV infection. “The prevalence of FM in inactive hepatitis B carriers were 23%. We also found, for the first time, that the frequency of FM in chronic active hepatitis patients was 21% (1).”
This means that those with Fibromyalgia need a remedy specifically designed to target the latent hepatitis virus. Gene-Eden-VIR is such a remedy.
“For a long time, we’ve said that latent viruses can cause disease. These findings provide evidence to substantiate this belief.” – Mike Evans, polyDNA
A study published on August 12, 2013 in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced hepatitis symptoms. Study authors wrote that, “Individuals infected with HCV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (2).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (2).”
To learn more about Gene-Eden-VIR, and hepatitis, visit http://gene-eden-kill-virus.com/hepatitis-B-Virus.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
References:
(1) The prevalence of fibromyalgia among patients with hepatitis B virus infection. Published on September 25, 2013.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798217/
(2) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11366600.htm
Published: November 28, 2013 7:49 AM
A study published on September 25 in The International Journal of Clinical and Experimental Medicine found that Fibromyalgia (FM) “prevalence was found to be as high as 25% in a single study of hepatitis B virus (HBV) carriers (1).” polyDNA recommends Gene-Eden-VIR to help the immune system target the latent HCV and HBV.
Rochester, NY (PRWEB) November 28, 2013
Patients with life-long infections of the hepatitis B and hepatitis C viruses tend to develop Fibromyalgia (FM). “(FM) is a syndrome characterized by widespread and chronic musculoskeletal pain, fatigue, morning stiffness, and sleep disturbance. The condition affects middle-aged women, in particular, and FM prevalence in the general population is thought to be as high as 2% (1).” However, “the prevalence of FM is higher in patients with Lyme disease, and those with HIV and hepatitis C virus (HCV) infections (1).” In addition, “FM prevalence was found to be as high as 25% in a single study of hepatitis B virus (HBV) carriers (1).” Compare the numbers, 2% in the general population versus 25% in hepatitis B patients.
Researchers found that Fibromyalgia was more prevalent in those with a latent HBV infection. “The prevalence of FM in inactive hepatitis B carriers were 23%. We also found, for the first time, that the frequency of FM in chronic active hepatitis patients was 21% (1).”
This means that those with Fibromyalgia need a remedy specifically designed to target the latent hepatitis virus. Gene-Eden-VIR is such a remedy.
“For a long time, we’ve said that latent viruses can cause disease. These findings provide evidence to substantiate this belief.” – Mike Evans, polyDNA
A study published on August 12, 2013 in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced hepatitis symptoms. Study authors wrote that, “Individuals infected with HCV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (2).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (2).”
To learn more about Gene-Eden-VIR, and hepatitis, visit http://gene-eden-kill-virus.com/hepatitis-B-Virus.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
References:
(1) The prevalence of fibromyalgia among patients with hepatitis B virus infection. Published on September 25, 2013.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798217/
(2) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11366600.htm
Well, the first study about fibromyalgia is genuine, but then Gene-Eden-VIR tried to jump on the bandwagon. Have a read of their so called
"Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. "
clinical study. The clinical study consisted of a questionnaire only, yep a single questionnaire filled by those who took their pill. That is. Oh, no HBV patients are involved.
No need to say anymore.
"Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013. "
clinical study. The clinical study consisted of a questionnaire only, yep a single questionnaire filled by those who took their pill. That is. Oh, no HBV patients are involved.
No need to say anymore.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
